Reneo Pharmaceuticals (RPHM)
(Delayed Data from NSDQ)
$1.31 USD
-0.10 (-7.09%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $1.36 +0.05 (3.82%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Reneo Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 83 | 54 | 40 | 20 | 15 |
Income After Depreciation & Amortization | -83 | -54 | -40 | -20 | -15 |
Non-Operating Income | 6 | 2 | 0 | 0 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -77 | -52 | -40 | -19 | -12 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -77 | -52 | -40 | -19 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -77 | -52 | -40 | -19 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -87 | -55 | -40 | -20 | -16 |
Depreciation & Amortization (Cash Flow) | -4 | -1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -83 | -54 | -40 | -20 | -15 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 30.68 | 24.50 | 18.14 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.52 | -2.12 | -2.19 | NA | NA |
Diluted Net EPS (GAAP) | -2.52 | -2.12 | -2.19 | -9.60 | NA |
Fiscal Year end for Reneo Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 6.36 | 9.56 | 25.00 | 20.89 | 21.04 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.36 | -9.56 | -25.00 | -20.89 | -21.04 |
Non-Operating Income | 1.00 | 1.14 | 1.45 | 1.69 | 1.51 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.36 | -8.43 | -23.55 | -19.20 | -19.53 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.36 | -8.43 | -23.55 | -19.20 | -19.53 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.36 | -8.43 | -23.55 | -19.20 | -19.53 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 33.42 | 33.42 | 33.12 | 33.81 | 30.22 |
Diluted EPS Before Non-Recurring Items | -0.16 | -0.25 | -0.70 | -0.57 | -0.65 |
Diluted Net EPS (GAAP) | -0.16 | -0.25 | -0.70 | -0.57 | -0.65 |